drugset / Trial / NCT03377101
Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This randomized phase II trial studies the side effects and how well fulvestrant and palbociclib with or without copanlisib work in treating patients with hormone receptor positive, HER2 negative, stage IV breast cancer. Fulvestrant, palbociclib, and copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2018-08-07
- Primary completion
- 2018-08-07
- Completion
- 2018-08-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Copanlisib | Small molecule | — | Intravenous |
| Background | Fulvestrant | Small molecule | — | Intramuscular |
| Background | Palbociclib | Small molecule | — | Oral |